Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, ph... von Brose, Marcia S, Dr, Cabanillas, Maria E, MD, Cohen, Ezra E W, Prof, Wirth, Lori J, MD, Riehl, Todd, PharmD, Yue, Huibin, PhD, Sherman, Steven I, Prof, Sherman, Eric J, MD

Volltext

Management of patients with NTRK fusion-positive thyroid cancer von Wirth, Lori J

Volltext

Still Perfecting Radioiodine in Thyroid Cancer, After All These Years von Wirth, Lori J

Volltext

PD-1 Blockade in Anaplastic Thyroid Carcinoma von Capdevila, Jaume, Wirth, Lori J., Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O., Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A., Fasolo, Angelica, Fuehrer, Dagmar, Huetter-Kroenke, Marie Luise, Forde, Patrick M., Wrona, Anna, Santoro, Armando, Sadow, Peter M., Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

Volltext

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, p... von Brose, Marcia S, Cabanillas, Maria E, Cohen, Ezra E W, Wirth, Lori J, Riehl, Todd, Yue, Huibin, Sherman, Steven I, Sherman, Eric J

Volltext

Cabozantinib in Progressive Medullary Thyroid Cancer von Elisei, Rossella, Schlumberger, Martin J, Müller, Stefan P, Schöffski, Patrick, Brose, Marcia S, Shah, Manisha H, Licitra, Lisa, Jarzab, Barbara, Medvedev, Viktor, Kreissl, Michael C, Niederle, Bruno, Cohen, Ezra E W, Wirth, Lori J, Ali, Haythem, Hessel, Colin, Yaron, Yifah, Ball, Douglas, Nelkin, Barry, Sherman, Steven I

Volltext

Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment von Nakaguro, Masato, Tada, Yuichiro, Faquin, William C., Sadow, Peter M., Wirth, Lori J., Nagao, Toshitaka

Volltext

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib von Rothenberg, S Michael, McFadden, David G, Palmer, Edwin L, Daniels, Gilbert H, Wirth, Lori J

Volltext

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer von Tahara, Makoto, Brose, Marcia S., Wirth, Lori J., Suzuki, Takuya, Miyagishi, Hideaki, Fujino, Katsuki, Dutcus, Corina E., Gianoukakis, Andrew

Volltext

Accelerated approvals hit the target in precision oncology von Subbiah, Vivek, Wirth, Lori J., Kurzrock, Razelle, Pazdur, Richard, Beaver, Julia A., Singh, Harpreet, Mehta, Gautam U.

Volltext

Medullary Thyroid Cancer: Updates and Challenges von Gild, Matti L, Clifton-Bligh, Roderick J, Wirth, Lori J, Robinson, Bruce G

Volltext

Treatment‐emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT) von Wirth, Lori J., Tahara, Makoto, Robinson, Bruce, Francis, Sanjeev, Brose, Marcia S., Habra, Mouhammed Amir, Newbold, Kate, Kiyota, Naomi, Dutcus, Corina E., Mathias, Elton, Guo, Matthew, Sherman, Steven I., Schlumberger, Martin

Volltext

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study von Bauml, Joshua, Seiwert, Tanguy Y, Pfister, David G, Worden, Francis, Liu, Stephen V, Gilbert, Jill, Saba, Nabil F, Weiss, Jared, Wirth, Lori, Sukari, Ammar, Kang, Hyunseok, Gibson, Michael K, Massarelli, Erminia, Powell, Steven, Meister, Amy, Shu, Xinxin, Cheng, Jonathan D, Haddad, Robert

Volltext

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer von Schlumberger, Martin, Tahara, Makoto, Wirth, Lori J, Robinson, Bruce, Brose, Marcia S, Elisei, Rossella, Habra, Mouhammed Amir, Newbold, Kate, Shah, Manisha H, Hoff, Ana O, Gianoukakis, Andrew G, Kiyota, Naomi, Taylor, Matthew H, Kim, Sung-Bae, Krzyzanowska, Monika K, Dutcus, Corina E, de las Heras, Begoña, Zhu, Junming, Sherman, Steven I

Volltext

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer von Wirth, Lori J., Brose, Marcia S., Sherman, Eric J., Licitra, Lisa, Schlumberger, Martin, Sherman, Steven, Bible, Keith C., Robinson, Bruce, Rodien, Patrice, Godbert, Yann, De La Fouchardiere, Christelle, Newbold, Kate, Nutting, Christopher, Misir, Soamnauth, Xie, Ran, Almonte, Ana, Ye, Weifei, Cabanillas, Maria E.

Volltext

Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma von Gigliotti, Benjamin J., Brooks, Jennifer A., Wirth, Lori J.

Volltext

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study von Subbiah, Vivek, Hu, Mimi I, Wirth, Lori J, Schuler, Martin, Mansfield, Aaron S, Curigliano, Giuseppe, Brose, Marcia S, Zhu, Viola W, Leboulleux, Sophie, Bowles, Daniel W, Baik, Christina S, Adkins, Douglas, Keam, Bhumsuk, Matos, Ignacio, Garralda, Elena, Gainor, Justin F, Lopes, Gilberto, Lin, Chia-Chi, Godbert, Yann, Sarker, Debashis, Miller, Stephen G, Clifford, Corinne, Zhang, Hui, Turner, Christopher D, Taylor, Matthew H

Volltext

Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma von Wirth, Lori J

Volltext

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer von Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J, Dutcus, Corina E, Song, James, Taylor, Matthew H, Kim, Sung-Bae, Krzyzanowska, Monika K, Capdevila, Jaume, Sherman, Steven I, Tahara, Makoto

Volltext

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit von Wirth, Lori J, Durante, Cosimo, Topliss, Duncan J, Winquist, Eric, Robenshtok, Eyal, Iwasaki, Hiroyuki, Luster, Markus, Elisei, Rossella, Leboulleux, Sophie, Tahara, Makoto

Volltext